Daily Ards Research Analysis
Analyzed 7 papers and selected 3 impactful papers.
Summary
Analyzed 7 papers and selected 3 impactful articles.
Selected Articles
1. Post-acute organ complications within one year following COVID-19 hospitalization and related socioeconomic inequalities.
Using three national registries and overlap propensity score weighting, this case-control study of 59,351 adults found higher 1-year cardiovascular (OR 1.19) and pulmonary (OR 2.05) complications after severe COVID-19 versus non-COVID hospitalization, with greater odds after critical illness (ICU and/or ARDS). Low income independently increased post-acute pulmonary complications among severe cases.
Impact: This large, registry-linked analysis quantifies organ-specific long-term risks and reveals socioeconomic disparities, informing post-acute care planning after COVID-19, especially following critical illness.
Clinical Implications: Prioritize structured 1-year follow-up for cardiovascular and pulmonary complications after COVID-19 hospitalization, with intensified surveillance after ICU/ARDS and targeted support for low-income patients.
Key Findings
- Higher 1-year cardiovascular complications after severe COVID-19 vs non-COVID hospitalization (overlap PS-weighted OR 1.19, 95% CI 1.03–1.37).
- Higher 1-year pulmonary complications after severe COVID-19 (overlap PS-weighted OR 2.05, 95% CI 1.80–2.34).
- Odds of post-acute complications were particularly elevated following critical COVID-19 (ICU and/or ARDS).
- Among severe COVID-19 patients, low income increased odds of post-acute pulmonary complications (aOR 1.53, 95% CI 1.05–2.25).
Methodological Strengths
- Nationwide linkage of three health and social registries with large sample size (N=59,351).
- Overlap propensity score weighting and severity stratification (severe vs critical defined by ICU and/or ARDS).
Limitations
- Observational case-control design cannot eliminate residual confounding.
- Registry-based outcome ascertainment may introduce misclassification; generalizability may be country-specific.
Future Directions: Prospective multi-country cohorts to validate risks, mechanistic studies linking critical illness/ARDS to long-term organ injury, and interventions to mitigate socioeconomic disparities.
Post-acute organ complications following COVID-19 hospitalization and potential socioeconomic inequalities therein are understudied. In this case-control study, we use individual-level data from three national health and social registries in Belgium to assess whether COVID-19 hospitalization increases the risk of post-acute organ complications within one year among 59,351 hospitalized adults without preexisting conditions affecting the specific organ system under study at baseline. In addition, we identify socioeconomic patterns in the development of these organ complications. Overlap propensity score (PS)-weighted odds ratios (ORs) and adjusted odds ratios (aORs) were estimated. All analyses were stratified between severe and critical COVID-19 hospitalization, with the latter defined by intensive care unit admission and/or the onset of acute respiratory distress syndrome. We found significant cardiovascular (overlap PS-weighted OR 1.19, 95% CI 1.03-1.37) and pulmonary (overlap PS-weighted OR 2.05, 95% CI 1.80-2.34) complications within one year following severe COVID-19 hospitalization compared to non-COVID-19 hospitalization, with particularly higher odds following critical COVID-19 hospitalization. Among severe COVID-19 patients, those with low income, compared to those with high income, had higher odds of post-acute pulmonary complications (aOR 1.53, 95% CI 1.05-2.25). Long-term care should prioritize monitoring organ complications following COVID-19 hospitalization, especially after critical illness.
2. An algorithm to identify less invasive surfactant administration using a real-world database of preterm infants.
Using chart review as gold standard, a LASSO-based model with 21 variables identified LISA in preterm infants with strong discrimination (AUROC 0.87). At a high-specificity threshold (≥0.79), the algorithm achieved 96.8% specificity and 90.0% PPV, with consistent performance across gestational ages.
Impact: By enabling accurate identification of LISA in administrative datasets lacking procedure codes, this algorithm unlocks large-scale real-world evaluations of neonatal respiratory care.
Clinical Implications: Supports benchmarking of LISA utilization and outcome studies across health systems; high specificity/PPV favor reliable case capture for effectiveness and safety evaluations.
Key Findings
- Among 1,263 preterm infants receiving surfactant, 36.6% were treated via LISA and 63.4% via invasive modalities (ETT or INSURE).
- A LASSO-based 21-variable model achieved AUROC 0.87 for identifying LISA in administrative data.
- At predicted probability ≥0.79, performance was: sensitivity 43.9%, specificity 96.8%, PPV 90.0%, NPV 72.5%, overall agreement 75.9%.
- Sensitivity and specificity were consistent across gestational-age subgroups; validation included a 2024 birth cohort.
Methodological Strengths
- Gold-standard chart review labeling with separate training/testing and temporal validation (2019–2024).
- Regularized modeling (LASSO) with AUROC-based discrimination and subgroup performance assessment by gestational age.
Limitations
- Moderate sensitivity may miss a portion of LISA cases, depending on the chosen threshold.
- Single integrated health system (KPNC) may limit generalizability; administrative coding practices can vary.
Future Directions: External validation across diverse health systems, optimization to improve sensitivity, and integration with unstructured EHR data (e.g., NLP) to enhance capture.
BACKGROUND: Surfactant replacement therapy is central to respiratory distress syndrome (RDS) management in preterm infants, which can be delivered using a variety of methods. Less invasive surfactant administration (LISA) has been increasingly adopted due to its association with improved neonatal outcomes. However, there are no procedure codes to identify LISA in large real-world data (RWD), limiting the ability to evaluate its use and effectiveness on a large scale. This study aimed to develop an algorithm to identify LISA procedures using administrative data. METHODS: We conducted a retrospective study using chart reviews as the gold standard to identify preterm infants receiving surfactant via LISA or non-LISA procedures across Kaiser Permanente Northern California (KPNC) facilities. We selected 82 candidate variables from administrative data between birth and date of first surfactant administration. The algorithm was developed using births between 2019 and 2023, which were randomly split into a training set (n = 884) and testing set (n = 379). A least absolute shrinkage and selection operator (LASSO) regression was used for variable selection and model fitting. Model discrimination was evaluated using area under the receiver operating characteristic (AUROC). Algorithm performance was validated using a combined sample of the testing set and a 2024 birth cohort (n = 622) overall and by gestational age (GA) using sensitivity (Sn), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV). RESULTS: Among 1,263 preterm infants who received surfactant, 462 (36.6%) received surfactant via LISA and 801 (63.4%) received surfactant via invasive modalities (ETT or INSURE). The LASSO-based model selected 21 variables predictive of LISA methods based on the training set. The model demonstrated strong discrimination (AUROC = 0.87). Using the maximum specificity cut-point (predicted probability ≥0.79), the model achieved Sn = 43.9%, Sp = 96.8%, PPV = 90.0% and NPV = 72.5%, with an overall agreement of 75.9% when evaluated in the combined testing set and 2024 birth cohort. Sn and Sp were consistent across GA subgroups. CONCLUSIONS: We used a machine-learning approach to develop an algorithm that performed well in identifying surfactant administered via LISA among preterm infants using administrative data. The algorithm demonstrated strong performance and can support future research to evaluate the utilization and outcomes of LISA using RWD.
3. Hypercapnia-Regulated Molecular Pathways: Mechanistic Insights Into CO₂-Driven Cellular Signaling and Therapeutic Implications.
This mechanistic review reframes hypercapnia as an active modulator driving noncanonical NF-κB signaling, Wnt-dependent impairment of alveolar repair, inflammasome activation, metabolic reprogramming, and epigenetic remodeling. It highlights tools (e.g., CarboSen) to isolate CO2 effects and proposes precision interventions with potential relevance to ARDS and chronic lung diseases.
Impact: By integrating CO2-specific signaling mechanisms and actionable targets, this review challenges permissive hypercapnia as uniformly benign and outlines testable precision therapies.
Clinical Implications: Encourages phenotype- and exposure-tailored management of hypercapnia in ARDS/COPD; suggests targeting macrophage Akt1, Wnt pathways, or leptin/STAT3/SOCS3 to improve immunity, repair, and ventilatory drive—requiring translational studies.
Key Findings
- Hypercapnia activates noncanonical NF-κB signaling and alters Wnt ligand secretion, impairing alveolar regeneration.
- CO2 exacerbates TLR4-primed NLRP3 inflammasome activation, with cell type–specific pro-inflammatory effects.
- Sustained hypercapnia induces metabolic reprogramming and epigenetic changes (e.g., TET1 downregulation leading to CDH1 hypermethylation).
- CarboSen probes enable separation of CO2-specific effects from acidosis in buffered systems.
- Therapeutic concepts include macrophage-specific Akt1 inhibition, localized Wnt agonists, and leptin/STAT3/SOCS3 axis targeting.
Methodological Strengths
- Comprehensive synthesis across molecular pathways with emphasis on cell type specificity and exposure parameters.
- Critical appraisal of experimental tools (e.g., CarboSen) that dissect CO2 versus pH effects, enhancing translational relevance.
Limitations
- Narrative review susceptible to selection bias; many findings derive from preclinical models with species differences.
- Uncertain reversibility of epigenetic changes and limited direct clinical validation.
Future Directions: Human tissue validation of CO2-driven pathways, exposure–response mapping, and early-phase trials of pathway-targeted interventions in ARDS/COPD.
Long dismissed as a passive marker of ventilatory failure, elevated carbon dioxide (PaCO₂ > 45 mmHg) is now recognized as a potent signaling molecule that orchestrates complex cellular responses. This review synthesizes recent advances revealing how hypercapnia modulates fundamental processes, immune regulation, tissue repair, and metabolism, through direct molecular mechanisms. We detail how CO₂ triggers noncanonical NF-κB signaling, alters Wnt ligand secretion to impair alveolar regeneration, and exacerbates TLR4-primed NLRP3 inflammasome activation; this pro-inflammatory effect is most prominent in specific cell types like microglia and under conditions of sustained high CO₂ levels. Furthermore, hypercapnia drives profound metabolic reprogramming and induces lasting epigenetic changes, such as TET1-downregulation-mediated CDH1 hypermethylation, which reinforces immunosuppression in chronic lung disease. Critically, we evaluate emerging tools like CarboSen probes that enable more precise separation of CO₂-specific effects from associated acidosis in buffered experimental systems. Therapeutically, these insights argue for precision strategies: macrophage-specific Akt1 inhibition to restore antiviral immunity, localized Wnt agonists to promote repair, or targeting the leptin/STAT3/SOCS3 axis to improve ventilatory drive. However, translation requires navigating significant species differences and unresolved questions regarding epigenetic reversibility. By framing hypercapnia not as a uniform stressor but as a complex modulator whose effects are dictated by concentration, duration, and the specific tissue type involved, this review charts a course toward targeting CO₂-driven signaling for therapeutic benefit in conditions ranging from ARDS and COPD to obesity hypoventilation syndrome.